Vasomune Announced the Government of Canada’s Investment in AV-001 Targeting COVID-19

Ontario Industry Updates
Written By Maura Campbell
vasomune_logo-small.jpg

Vasomune announced that the company has received a substantial investment on behalf of the Government of Canada through the National Research Council (NRC) for Vasomune’s continued development of AV-001, the company’s lead candidate drug targeting COVID-19.

Maura Campbell
Previous

Logibec Expands into Virtual Care with Ontario-based Acquisition
Next

Huron Digital Pathology Receives CE-IVD Mark for TissueScope iQ Scanner